Attached files
| file | filename |
|---|---|
| EX-10.10 - EX-10.10 - Candel Therapeutics, Inc. | d120909dex1010.htm |
| EX-10.9 - EX-10.9 - Candel Therapeutics, Inc. | d120909dex109.htm |
| EX-10.8 - EX-10.8 - Candel Therapeutics, Inc. | d120909dex108.htm |
| EX-10.7 - EX-10.7 - Candel Therapeutics, Inc. | d120909dex107.htm |
| EX-4.5 - EX-4.5 - Candel Therapeutics, Inc. | d120909dex45.htm |
| EX-4.2 - EX-4.2 - Candel Therapeutics, Inc. | d120909dex42.htm |
| S-1 - S-1 - Candel Therapeutics, Inc. | d120909ds1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the use of our report dated March 29, 2021, with respect to the consolidated financial statements of Candel Therapeutics, Inc., included herein and to the reference to our firm under the heading “Experts” in the prospectus.
| /s/ KPMG LLP |
McLean, Virginia
June 25, 2021